There’s an increasing buzz among patients for GLP-1 weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy, but if patient demand continues to grow and Medicare expanded its coverage in response, it could cost the federal program between $13.6 and $26.8 billion annually.